ReviewSeminars in immunopathology2011
In vitro immunogenicity of undifferentiated pluripotent stem cells (PSC) and derived lineages.
Review in Seminars in immunopathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Transplantation of Human Neural Progenitor Cells (NPC) into Putamina of Parkinsonian Patients: A Case Series Study, Safety and Efficacy Four Years after Surgery.Cell transplantation · 2019Trial
- Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.Stem cell research & therapy · 2024Review
- Human-Induced Pluripotent Stem Cells in Plastic and Reconstructive Surgery.International journal of molecular sciences · 2024Review
- HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives.Scientific reports · 2017Article
- Emerging Implications for Extracellular Matrix-Based Technologies in Vascularized Composite Allotransplantation.Stem cells international · 2016Review
- Article
- Can pluripotent stem cells be used in cell-based therapy?Cellular reprogramming · 2014Review
- The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.The Journal of biological chemistry · 2014Review
- Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.Regenerative medicine · 2014Article
- Progress and prospects for genetic modification of nonhuman primate models in biomedical research.ILAR journal · 2013Review
- Article
- Administration of bone marrow derived mesenchymal stem cells into the liver: potential to rescue pseudoxanthoma elasticum in a mouse model (Abcc6-/-).Journal of biomedicine & biotechnology · 2012Article
- Human pluripotent stem cell-based approaches for myocardial repair: from the electrophysiological perspective.Molecular pharmaceutics · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The observation that embryonic stem cells (ESCs) expressed reduced levels of major histocompatibility (MHC) class I genes, no MHC class II or costimulatory molecules suggested early on that pluripotent stem cells (PSCs) could be "immune-privileged" and were unable to induce immune reactions. However, soon it became apparent that in some instances, ESCs were recognized by immune cells but still could reduce an active and strong immune response. Similar results were obtained with other PSCs. Almost 10 years later, the exact mechanisms are still not well understood and seem to differ between the different human and rodent PSC lines (even between different murine cell lines). These differences could be due to differing experimental approaches, different derivation protocols (to obtain the PSC lines), species specificity, or genetic background of the cells lines. A better understanding of the immune regulatory mechanisms deployed by PSCs and early derivates may inform us on immune regulation and could be exploitable for regenerative medicine using allogeneic cells. As PSCs grow robustly in culture and can easily be gene-modified, one could envision the generation of cell lines that maintain these immune suppressive properties through terminal differentiation, thus generating universal donor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.